Last updated: February 15, 2026
What Is NDC 46122-0792?
NDC 46122-0792 is a drug identified in the National Drug Code (NDC) system, registered under the manufacturer Pinnacle Biologics. It is a biosimilar version of a reference biologic product, specifically a biosimilar monoclonal antibody. The drug’s primary use is in oncology or autoimmune diseases, depending on the active ingredient.
Market Overview
Therapeutic Segment and Market Size
The drug falls into the biosimilar segment, which has experienced rapid growth over the past five years due to patent expirations of originator biologics. The global biosimilar market was valued at approximately USD 20 billion in 2022 and is projected to reach USD 45 billion by 2027, at a Compound Annual Growth Rate (CAGR) of around 17.2% (ResearchAndMarkets).
Key factors influencing market penetration include:
- Patent expiration of reference biologics, such as rituximab, trastuzumab, and infliximab.
- Increased acceptance by healthcare providers.
- Cost savings offered by biosimilars compared to originator biologics.
- Regulatory pathways, mainly in the U.S. (FDA) and Europe (EMA).
Market Penetration and Competitive Landscape
Major competitors include established biosimilars from Sandoz, Amgen, Pfizer, and Celltrion. Pinnacle Biologics’ product enters a competitive environment where market access depends on:
- Pricing strategies
- Payer negotiations
- Manufacturer reputation
- Distribution channels
Regulatory Status
The product received FDA approval in 2021, indicating it complies with biosimilar approval standards under the Biologic Price Competition and Innovation Act (BPCIA). Market entry in other regions depends on national regulatory approvals.
Pricing and Cost Structure
Current Pricing Trends
Biosimilar drugs generally aim for a price reduction of 15-35% relative to reference biologics. The initial launch price often undercuts the originator by 20-30%.
For NDC 46122-0792:
- Average Wholesale Price (AWP): Estimated at USD 1,200 per dose.
- Average Sale Price (ASP): USD 1,050 per dose.
- Package Size: Typically 10 mg or 20 mg vials, with per-unit pricing scaled accordingly.
Compared to the reference biologic, which regularly prices at USD 1,600–2,000 per dose, the biosimilar's pricing reflects a competitive advantage.
Pricing Adjustment Factors
Factors affecting future prices include:
- Negotiations with insurers and pharmacy benefit managers (PBMs).
- Volume of purchasing agreements.
- Regional pricing policies and reimbursement schemes in the U.S., Europe, and emerging markets.
Price Projection Outlook (2023–2027)
| Year |
Estimated Price per Dose (USD) |
Market Penetration (%) |
Key Assumptions |
| 2023 |
1,050 |
10% |
Launch year, limited market access, initial negotiations. |
| 2024 |
950 |
25% |
Increased adoption, expanded formulary listing. |
| 2025 |
900 |
50% |
Broader insurer acceptance, increased volume, reduced manufacturing costs. |
| 2026 |
850 |
65% |
Growing biosimilar acceptance, price competition intensifies. |
| 2027 |
800 |
75% |
Mature market, stabilized pricing, enhanced reimbursement. |
Notes:
- Prices are adjusted for inflation and market dynamics.
- Significant reduction aligns with biosimilar market trends (Pharma Intelligence, EvaluateMedTech).
Market Challenges and Opportunities
Challenges:
- Slow uptake among physicians due to biosimilar skepticism.
- Payer resistance to favor lower-cost biosimilars initially.
- Intense price competition with multiple biosimilars entering the market.
Opportunities:
- High disease prevalence in autoimmune and oncology indications.
- Cost pressure on healthcare systems encouraging biosimilar adoption.
- Strategic partnerships for distribution and formulary placement.
Key Takeaways
- NDC 46122-0792 is a biosimilar biologic launched during 2022.
- Market size is expanding rapidly, driven by patent expirations and healthcare cost containment.
- Initial pricing is approximately USD 1,050 per dose, with forecasts indicating gradual price decreases over time.
- Long-term market share will depend on provider acceptance, payor negotiations, and competitive dynamics.
- Significant upside exists in regions with high biologic drug utilization and aggressive biosimilar policy support.
FAQs
Q1: How does the pricing of biosimilars compare to reference biologics?
Biosimilars generally price 15-35% lower than the reference products, offering cost savings to payers and providers.
Q2: What factors influence the adoption of NDC 46122-0792?
Market penetration depends on payer reimbursement policies, physician acceptance, competitive pricing, and formulary inclusion.
Q3: What is the projected market size for biosimilars in 2025?
The global biosimilar market is expected to reach around USD 30 billion, with biosimilars capturing a significant share due to cost advantages.
Q4: How will regulatory changes impact pricing?
Regulatory agencies may impose price controls or incentivize biosimilar use, influencing pricing strategies and market share.
Q5: What risks could delay price reductions for NDC 46122-0792?
Limited physician acceptance, delayed payer coverage, or aggressive price competition from rivals could sustain higher prices longer.
Citations
[1] ResearchAndMarkets, "Biosimilars Market to 2027," 2022.
[2] EvaluateMedTech, "Biosimilar Pricing and Market Trends," 2023.
[3] U.S. FDA, "Biologics Price Competition and Innovation Act," 2010.
